logo-header-min.png
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 14, 2024 16:30 ET | Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study MT-601 was well tolerated with no observation of...
logo-header-min.png
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
August 12, 2024 07:00 ET | Marker Therapeutics
HOUSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for...
Targretin Main Life
萬聯行在香港獲得Targretin®️(Bexarotene)用於皮膚T細胞淋巴瘤的上市批准
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
香港和澳門的獲批為Targretin®️首次在中國區域內上市Bexarotene為國際臨床慣例用於治療復發性皮膚T細胞淋巴瘤(CTCL)的標準藥物 香港, July 16, 2024 (GLOBE NEWSWIRE) --...
Targretin Main Life
万联行获得Targretin®(Bexarotene 贝沙罗汀)在香港用于皮肤T细胞淋巴瘤的市场批准
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
香港和澳门的批准标志着Targretin®首次在中国上市贝沙罗汀代表国际临床实践中对复发性皮肤T细胞淋巴瘤(CTCL)的标准治疗 香港, July 16, 2024 (GLOBE NEWSWIRE) -- 万联行有限公司(“Main Life”)今天宣布Targretin®(贝沙罗汀)胶囊在香港获得上市许可,用于治疗至少一次系统治疗无效的皮肤T细胞淋巴瘤 (Cutaneous T-cell...
Targretin Main Life
Main Life received Targretin® (Bexarotene) Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma
July 16, 2024 02:54 ET | MAIN LIFE CORPORATION LIMITED
Targretin® (Bexarotene) received Marketing Authorisation in Hong Kong for Cutaneous T-Cell Lymphoma.
ADCT_4C_TM-R .png
ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 07:15 ET | ADC Therapeutics SA
LAUSANNE, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will present a company overview at the Jefferies...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics to Participate in Upcoming Investor Conferences
May 28, 2024 08:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics to Participate in Upcoming Investor Conferences
logo-header-min.png
Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 15, 2024 16:15 ET | Marker Therapeutics
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study Study participant with Non-Hodgkin’s Lymphoma who...
cargo-logo-full-color-rgb-1165px@300ppi.png
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET | Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Tevogen Logo Notified.png
Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
April 11, 2024 08:05 ET | Tevogen Bio Inc
Tevogen’s Chief Scientific Officer explains the company’s oncology pipeline strategy as it relates to harnessing Cytotoxic T Lymphocytes to target cancers.